Publication Year

Wallace E, Sacks NC, Cyr P, Baker-Wagner M. An observational cohort analysis on the economic impact of chronic kidney disease in patients with fabry disease. Poster presentation, ISPOR Annual International Meeting, Virtual, May 2021.

Sacks NC, Healey B, Cyr PL, Slocomb T, James E, Beggs A, Graham RJ. Healthcare resource use and expenditures in patients with x-linked myotubular myopathy (XLMTM). Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, April 2021.

Panattoni L, Hernandez J, Liu Y, Sacks NC, Higham R, Stephenson B, Armstrong A. Initial treatment patterns for newly diagnosed, commercially insured patients with psoriasis. Poster presentation, ISPOR, April 2021.

Rehorn MR, Sacks NM, Cyr PL, Emden, MR, Sherwood R, Pokorney SD. Rates of catheter ablation for paroxysmal supraventricular tachycardia in the United States. J Am Coll Cardiol 77 (18-Sup1):330. Poster Contribution, American College of Cardiology, 2021.

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(Aug):104969; doi: 10.1016/j.yrtph.2021.104969.

Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. 2021. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis. The Oncologist 26(9):e1609–e1618; doi: 10.1002/onco.13822.

Sacks NC, Healey BE, Cyr PL, Slocomb T, James E, Beggs AH, Graham RJ. 2021. Costs and health resource use in patients with X-linked myotubular myopathy: insights from U.S. commercial claims. J Manag Care Spec Pharm 27(8):1019–1026.

Chew D, Sacks NC, Emden MR, Preib MT, Cyr PL, Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 132–140.

Rehorn M, Sacks NC, Emden MR, Healey B, Preib MT, Cyr PL, Pokorney SD. 2021. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol 32(8):2199-2206; doi: 10.1111/jce.15109.